# Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

> **NCT01489189** · PHASE3 · COMPLETED · sponsor: **Jaeb Center for Health Research** · enrollment: 305 (actual)

## Conditions studied

- Proliferative Diabetic Retinopathy

## Interventions

- **OTHER:** Prompt Panretinal Photocoagulation
- **DRUG:** 0.5-mg Ranibizumab
- **OTHER:** Deferred panretinal photocoagulation

## Key facts

- **NCT ID:** NCT01489189
- **Lead sponsor:** Jaeb Center for Health Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2015-01
- **Final completion:** 2018-02-05
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01489189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01489189, "Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01489189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*